Want to see KE full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.41Last Year’s EPS
0.34Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a cautiously positive tone: the company reported sequential revenue growth, strong and accelerating Medical performance (now ~30% of revenue), margin improvement, continued positive operating cash flow, improved liquidity and affirmed full-year guidance. At the same time, management highlighted near-term pressures—reported YoY revenue decline (when unadjusted), soft Automotive and Industrial demand, margin headwinds from the Indianapolis ramp in FY'27, higher SG&A as a percent of sales, and macro/geopolitical risks. Strategic initiatives (Indianapolis facility, Medical CMO focus, active M&A pursuit) and solid balance sheet position offer upside, while the timing of CMO ramps and external demand trends represent meaningful near-term risks.Company Guidance
Medical Revenue Strength and Portfolio Milestone
Medical sales were $106 million (30% of company revenue), up 10% sequentially. Adjusting for a prior-year consigned inventory sale, Medical grew ~17% year-over-year in Q3 and is up 15% year-to-date, marking a third consecutive quarter of double-digit Medical growth. Asia Medical growth in Q3 exceeded 20%.
Sequential Revenue Growth and Normalized YoY Improvement
Total net sales were $352.9 million, up 3.4% sequentially. Reported year-over-year sales declined 6%, but when normalizing for the prior-year $24 million consigned inventory sale, company revenue increased nearly 1% year-over-year.
Margin and Profitability Gains
Gross margin improved to 7.9% from 7.2% a year ago (a 70 basis point increase). Adjusted operating income was $14.8 million (4.2% of sales). Adjusted net income was $8.0 million, or $0.33 per diluted share, versus $6.8 million, or $0.27, in the prior-year quarter.
Strong Cash Generation and Liquidity
Cash and cash equivalents were $82.5 million. Cash from operations was positive $14.9 million in the quarter — the ninth consecutive quarter of positive operating cash flow. Cash conversion days improved to 90 (1-day sequential improvement, 9-day YoY improvement). Total short-term liquidity (cash + unused credit) was $358.5 million and the $300 million revolver was renewed.
Balance Sheet and Capital Deployment
Borrowings were $163 million (down ~$15.8 million, ~9% YoY). Inventory declined to $273.3 million (down $23.3 million, or 8% YoY). The company repurchased $4 million of shares in Q3 and has returned $113.5 million to shareholders since 2015.
Lower Interest Expense and Improved Tax Rate
Other expense declined to $3.0 million from $4.6 million a year ago as interest expense fell nearly 30% year-over-year. The effective tax rate improved to 34.9% from 46.6% in the prior-year quarter, with an expected full-year rate of ~30%.
Affirmed Guidance and Strategic Growth Initiatives
Company reaffirmed fiscal 2026 revenue guidance of $1.40–$1.46 billion and expects adjusted operating margin at the high end of the 4.2%–4.5% range. Q4 sales are guided to $370–$380 million with adjusted OI margin of 4.4%–4.6%. The Indianapolis 300,000 sq. ft. medical facility is expected to begin production by year-end and the company is actively pursuing M&A tuck-ins to accelerate Medical CMO growth.
KE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
KE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $27.15 | $25.16 | -7.33% |
Feb 04, 2026 | $30.72 | $23.55 | -23.34% |
Nov 05, 2025 | $30.38 | $28.16 | -7.31% |
Aug 13, 2025 | $20.97 | $24.71 | +17.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kimball Electronics Inc (KE) report earnings?
Kimball Electronics Inc (KE) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is Kimball Electronics Inc (KE) earnings time?
Kimball Electronics Inc (KE) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KE EPS forecast?
KE EPS forecast for the fiscal quarter 2026 (Q4) is 0.41.